Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Drug Review At US FDA: Has Submission Rush Ended Or Just Paused?

Executive Summary

Excitement to get a 10-month ANDA review may have waned in January as submissions plummet, but can approvals keep up?

Advertisement

Related Content

Generic Drug Review: US FDA Approves More ANDAs Than It Receives For First Time Since Early 2016
ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System
Generic Application Quality Showing Signs Of Improvement
Another ANDA Submission Surge Begins
ANDA Approvals, Complete Responses Hit Record In FY 2016
Dark, Then Dawn: ANDA Workload Approaching Steady State After 2014 Eruption
ANDA Lull Begins: OGD Receives Four Applications In July

Topics

Advertisement
UsernamePublicRestriction

Register

PS119988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel